| scholarly article | Q13442814 |
| P2093 | author name string | Bruce L Roberts | |
| Michael J Turner | |||
| Johanne M Kaplan | |||
| Jacqueline Shields | |||
| Elizabeth Hutto | |||
| Yanping Hu | |||
| William M Siders | |||
| Matthew S Gale | |||
| P2860 | cites work | Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab | Q28217802 |
| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis | Q33381736 | ||
| CD52 antigen--a review. | Q33938864 | ||
| Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia | Q34395747 | ||
| CD52 (CAMPATH1). | Q34541444 | ||
| A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation | Q36194538 | ||
| Rationale for cytotoxic monoclonal antibodies in MS. | Q36905020 | ||
| Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab | Q36986787 | ||
| Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells | Q39775657 | ||
| CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki | Q40037876 | ||
| Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model | Q40355709 | ||
| Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. | Q40476622 | ||
| Effect of alemtuzumab on neoplastic B cells. | Q40482330 | ||
| Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells | Q40993369 | ||
| Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers | Q41847767 | ||
| Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. | Q45032703 | ||
| Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism | Q46845177 | ||
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. | Q50766232 | ||
| Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. | Q51987968 | ||
| Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. | Q53595595 | ||
| CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. | Q53615894 | ||
| Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis | Q61651685 | ||
| The CAMPATH-1 antigen (CDw52) | Q61651748 | ||
| Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H | Q71257873 | ||
| Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils | Q71930114 | ||
| Effect of Campath-1H antibody on human hematopoietic progenitors in vitro | Q72088966 | ||
| Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes | Q72159431 | ||
| Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung | Q73429984 | ||
| Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H | Q74566806 | ||
| Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model | Q79367320 | ||
| Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H) | Q79405039 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 260-270 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Immunology | Q15754984 |
| P1476 | title | Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. | |
| P478 | volume | 128 |
| Q89873792 | A cell-based assay for the detection of neutralizing antibodies against alemtuzumab |
| Q35953466 | ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. |
| Q39744600 | Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. |
| Q61449792 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications |
| Q42908395 | Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses |
| Q54207057 | Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. |
| Q38371740 | Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy |
| Q30490389 | Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts |
| Q37679919 | Alemtuzumab and multiple sclerosis: therapeutic application |
| Q51745056 | Alemtuzumab as Treatment for Multiple Sclerosis. |
| Q40360876 | Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis |
| Q48106234 | Alemtuzumab depletion failure can occur in multiple sclerosis |
| Q38619696 | Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort |
| Q28080506 | Alemtuzumab for the treatment of multiple sclerosis |
| Q30808014 | Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis |
| Q30458930 | Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety |
| Q26800128 | Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond |
| Q64992762 | Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment. |
| Q42149544 | Alemtuzumab in allogeneic hematopoetic stem cell transplantation |
| Q38536770 | Alemtuzumab in multiple sclerosis: an update |
| Q42361890 | Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world |
| Q26849781 | Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use |
| Q37810989 | Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis |
| Q39474069 | Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes |
| Q33404568 | Alemtuzumab therapy for multiple sclerosis |
| Q37337775 | Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis |
| Q30053056 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial |
| Q47983705 | Alemtuzumab-induced remission of multiple sclerosis-associated uveitis |
| Q38262622 | Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis |
| Q38194115 | Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis |
| Q43074735 | Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment? |
| Q37579941 | An observational study of alemtuzumab following fingolimod for multiple sclerosis. |
| Q37427684 | Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma |
| Q58788563 | Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis |
| Q94597939 | Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double negative T cells and newly generated T and B cells |
| Q37866150 | Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy |
| Q43249169 | Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. |
| Q35116554 | Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection |
| Q37994136 | Antibody therapy for acute lymphoblastic leukemia |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q64038865 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings |
| Q38720045 | Both cladribine and alemtuzumab may effect MS via B-cell depletion |
| Q48664001 | Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis |
| Q36633574 | CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation |
| Q36113098 | CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment |
| Q28548044 | Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity |
| Q89486119 | Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies |
| Q59129976 | Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis |
| Q36369924 | Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. |
| Q40927126 | Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation |
| Q26830569 | Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets |
| Q90734654 | Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer |
| Q97570186 | Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review |
| Q38266338 | Current status of antibody therapy in ALL. |
| Q38164108 | Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia |
| Q36621100 | Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm |
| Q37690014 | Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis |
| Q38220740 | Drug safety evaluation of alemtuzumab for multiple sclerosis |
| Q47868767 | Drugs approved for the treatment of multiple sclerosis: review of their safety profile. |
| Q38101004 | Drugs in development for relapsing multiple sclerosis |
| Q38180157 | Established and novel disease-modifying treatments in multiple sclerosis |
| Q38722163 | Establishment a CHO Cell Line Expressing Human CD52 Molecule |
| Q89820664 | Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis |
| Q37191195 | Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity. |
| Q35589934 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). |
| Q89311925 | FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety |
| Q89450650 | Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions |
| Q37395089 | Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation |
| Q34326110 | Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis |
| Q38287572 | Immune reconstitution inflammatory syndrome associated with biologic therapy |
| Q38918124 | Impact of Immune-Modulatory Drugs on Regulatory T Cell |
| Q54125905 | Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. |
| Q48112332 | Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity |
| Q93098164 | Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis |
| Q56984212 | Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study |
| Q38173374 | Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis |
| Q36399264 | Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab |
| Q57187916 | Investigation Of The Effect Of Alemtuzumab In An Experimental Spinal Cord Trauma Model In Rats |
| Q91819064 | Keratinocyte growth factor impairs human thymic recovery from lymphopenia |
| Q57162830 | Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing |
| Q34376451 | Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. |
| Q89796128 | Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning |
| Q49539698 | Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
| Q27022540 | Monoclonal antibodies in acute lymphoblastic leukemia |
| Q26776234 | Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes |
| Q21131216 | Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies |
| Q30252776 | New Therapeutic Strategies in Acute Lymphocytic Leukemia |
| Q37777362 | Novel Targets for Treatment of Adult Acute Lymphocytic Leukemia |
| Q38120551 | Novel targeted therapies in acute lymphoblastic leukemia |
| Q40314122 | Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia |
| Q89666188 | PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion |
| Q37362699 | Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys |
| Q42699618 | Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program |
| Q33980435 | Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies |
| Q28078076 | Recent advances and novel treatment paradigms in acute lymphocytic leukemia |
| Q38291696 | Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer |
| Q39032832 | Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. |
| Q39409394 | Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. |
| Q64098085 | Risks and risk management in modern multiple sclerosis immunotherapeutic treatment |
| Q39178547 | Role of Memory T Cells in Allograft Rejection and Tolerance |
| Q34542922 | Safety of monoclonal antibodies for the treatment of multiple sclerosis. |
| Q36026719 | Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. |
| Q50858454 | Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. |
| Q36245171 | T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice. |
| Q38750505 | Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation |
| Q38930113 | The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer |
| Q39532967 | The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. |
| Q89965705 | The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies |
| Q38747419 | The immunological function of CD52 and its targeting in organ transplantation |
| Q38089599 | The role of natural killer cells in multiple sclerosis and their therapeutic implications |
| Q82978420 | The utility of cytodiagnostic urinalysis as a tool to diagnose kidney allograft dysfunction in the era lymphocyte-depleting induction therapy |
| Q30869048 | Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy |
| Q37737305 | Treating multiple sclerosis with monoclonal antibodies: a 2010 update. |
| Q44757011 | Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program |
| Q86992836 | [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies] |
| Q82261906 | [Alemtuzumab: a further option for treatment of multiple sclerosis] |
| Q28069730 | Alemtuzumab for Multiple Sclerosis. |
Search more.